Clinical Trial Update: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) [Phase 2]

View source ↗

Summary

A Phase 2 rollover study to provide continued Parsaclisib treatment for participants with B-cell malignancies who previously enrolled in Parsaclisib trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• Parsaclisib (parsaclisib)

Snippet

Sponsor: Incyte Corporation | Conditions: B-Cell Malignancies | Phase 2 | Status: ACTIVE_NOT_RECRUITING